High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers

By Horio Akiyo  

International Journal of Clinical Oncology, Vol. 17, Iss. 2, 2012-04 ,pp. : 131-136

Springer Publishing Company

Access to resources Recommend Favorite

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

By Sawaki Masataka  

Breast Cancer, Vol. 19, Iss. 3, 2012-07 ,pp. : 253-258

Springer Publishing Company

Access to resources Recommend Favorite

HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 8, Iss. 5, 2008-06 ,pp. : 488-496

Bentham Science Publishers

Access to resources Recommend Favorite

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

By Venturini M.   Bighin C.   Monfardini S.   Cappuzzo F.   Olmeo N.   Durando A.   Puglisi F.   Nicoletto O.   Lambiase A.   Mastro L.  

Breast Cancer Research and Treatment, Vol. 95, Iss. 1, 2006-01 ,pp. : 45-53

Springer Publishing Company

Access to resources Recommend Favorite

Premenopausal node-negative breast cancer: May adjuvant chemotherapy be indicated by the analysis of nuclear DNA dynamics?

By Wyss-desserich M-T.  

Breast Cancer Research and Treatment, Vol. 42, Iss. 3, 1997-02 ,pp. : 253-263

Springer Publishing Company

Access to resources Recommend Favorite